Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADK | P55263 | 4/20 | 0.44 |
| ▸ | METTL3 | Q86U44 | 13/20 | 0.43 |
| ▸ | RAPGEF3 | O95398 | 1/20 | 0.42 |
| ▸ | DOT1L | Q8TEK3 | 2/20 | 0.37 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.37 |
| ▸ | PRMT3 | O60678 | 1/20 | 0.37 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.37 |
| ▸ | NNMT | P40261 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31617998 | 0.89 | ADK (0.44) | ADKMETTL3RAPGEF3 | |
| SCHEMBL31618062 | 0.86 | ADK (0.44) | ADKMETTL3RAPGEF3PRMT5 | |
| SCHEMBL25047670 | 0.80 | METTL3 (0.34) | ADKMETTL3 | |
| SCHEMBL31617866 | 0.80 | METTL3 (0.34) | ADKMETTL3 | |
| SCHEMBL25046663 | 0.77 | ADK (0.46) | ADKMETTL3RAPGEF3 | |
| SCHEMBL25047977 | 0.76 | METTL3 (0.43) | ADKMETTL3RAPGEF3PRMT5 | |
| SCHEMBL24293550 | 0.76 | METTL3 (0.48) | ADKMETTL3RAPGEF3 | |
| SCHEMBL29478342 | 0.76 | METTL3 (0.48) | ADKMETTL3RAPGEF3 | |
| SCHEMBL20488516 | 0.75 | PRMT5 (0.46) | ADKMETTL3RAPGEF3PRMT5 | |
| SCHEMBL25047680 | 0.75 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250188110-A1 | SPECIFIC SMALL MOLECULE INHIBITORS THAT BLOCK KMT9 METHYLTRANSFERASE ACTIVITY AND FUNCTION | ALBERT-LUDWIGS-UNIVERSITÄT FREIBURG (DE) | 2025-06-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250188110-A1 | SPECIFIC SMALL MOLECULE INHIBITORS THAT BLOCK KMT9 METHYLTRANSFERASE ACTIVITY AND FUNCTION | KMT5A, KMT5B, KMT5C | ADK 1700/4885METTL3 166/4885RAPGEF3 1588/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.